Dakota Wealth Management Has $14.93 Million Stock Position in Medtronic PLC $MDT

Dakota Wealth Management grew its position in Medtronic PLC (NYSE:MDT) by 109.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 156,715 shares of the medical technology company’s stock after purchasing an additional 81,896 shares during the period. Dakota Wealth Management’s holdings in Medtronic were worth $14,926,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Delos Wealth Advisors LLC acquired a new position in Medtronic in the second quarter worth approximately $27,000. Corundum Trust Company INC bought a new stake in Medtronic in the third quarter worth approximately $27,000. Valley Wealth Managers Inc. acquired a new position in shares of Medtronic during the 3rd quarter worth $29,000. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medtronic during the 3rd quarter valued at $33,000. Finally, Tripletail Wealth Management LLC bought a new position in shares of Medtronic during the 3rd quarter valued at $34,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Up 1.7%

Shares of MDT stock opened at $98.54 on Tuesday. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The firm has a market cap of $126.33 billion, a PE ratio of 27.45, a price-to-earnings-growth ratio of 2.43 and a beta of 0.71. The stock has a 50 day moving average of $99.03 and a 200-day moving average of $96.80.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. Medtronic’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s dividend payout ratio is currently 79.11%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Royal Bank Of Canada upped their price objective on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Truist Financial decreased their price target on Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a research note on Wednesday, February 18th. UBS Group reissued a “neutral” rating and issued a $104.00 price objective on shares of Medtronic in a research note on Wednesday, February 4th. William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Finally, Sanford C. Bernstein increased their price target on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $110.84.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for its next‑gen GI Genius module and ColonPRO software — expands regulatory clearance and commercial runway in GI imaging, a clear revenue catalyst. Medtronic wins CE mark for next-gen GI Genius module, ColonPRO software
• Positive Sentiment: Recognized at the 2026 Dorian Awards for structured problem‑solving excellence — a reputational boost that supports brand value with hospitals and enterprise customers. 2026 DORIAN AWARDS RECOGNIZE GLOBAL LEADERS IN STRUCTURED PROBLEM-SOLVING EXCELLENCE
• Positive Sentiment: Multiple investor pieces highlight Medtronic’s strong dividend profile and defensive cash flows, reinforcing interest from income-seeking investors and supporting the share price floor. 1 Reason I’d Buy Medtronic Stock and Never Sell
• Neutral Sentiment: BTIG maintained a Hold rating on MDT — not bearish but keeps analyst sentiment from turning strongly positive. BTIG Sticks to Its Hold Rating for Medtronic (MDT)
• Neutral Sentiment: Valuation/returns analysis pieces point to mixed long‑term returns and prompt investors to reassess fair value — supports trading volatility but not a clear directional signal. Is It Time To Reconsider Medtronic (MDT) After Mixed Long Term Share Returns
• Neutral Sentiment: Industry podcast and revenue roundups highlight broader medtech winners from 2025 — useful context for sector positioning but not company‑specific catalysts. Podcast: Which pharma and medtech companies came out on top in 2025 revenues?
• Neutral Sentiment: Coverage of broader trade/tariff uncertainty underscores a macro risk — CEOs want policy clarity, which could affect multinational supply chains and sentiment for global medtech firms like Medtronic. Veteran CEO: President Trump’s chaotic tariff policy is not working

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).